FDA Clears Way for Generic Mupirocin Nasal Ointment
December 21, 2025
December 21, 2025
WASHINGTON, Dec. 21 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration issued a notice announcing its determination that the discontinuation of Bactroban nasal ointment was not due to safety or effectiveness concerns.
This decision provides a pathway for the agency to approve generic versions of the medication for the first time since the brand was discontinued.
Bactroban, a 2% mupirocin nasal ointment, was first approved in 1995 to . . .
This decision provides a pathway for the agency to approve generic versions of the medication for the first time since the brand was discontinued.
Bactroban, a 2% mupirocin nasal ointment, was first approved in 1995 to . . .